Deleted Tweets From Scott Gottlieb, R-D.C.

We’re taking new steps to bring some of the most significant modernizations to the FDA’s 510(k) program in a generation to help ensure new devices are evaluated against advances in technology that can improve safety and performance. https://t.co/EudSYtpWt0 https://t.co/aJgNOwZUwJ

RT @FDA_Drug_Info: Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions meeting begins this morning at 9am EST… https://t.co/qgKJFRITYM

RT @ZacharyBrennan: a quick look at today's #DrugShortagesMtg, where an FDA economist noted that shortages aren't just increasing but a… https://t.co/hW9ot8BUY7

1/3: Today I issued a statement that further explains why predicate modernization in the 510K medical device approval pathway is a key component of promoting innovation to help patients access safe and effective treatments. https://t.co/D6a74fT9Pa https://t.co/VlxpijPsa4

#FDA is committed to ensuring patients and healthcare providers have the most up-to-date information regarding ARB recalls. We’ll continue to post updates and recently posted a Q&A for patients and HCPs: https://t.co/EXl8c3HEIU

We've updated our list of valsartan products under recall to include certain lots of valsartan produced by Teva which contain the impurity NDEA. #FDA is carefully assessing all ARB medications and will continue to investigate. https://t.co/bRwqdjWIhR

RT @FDAOncology: Proposed patient-friendly definition of Progression-Free Survival: The amount of time after the start of this treat… https://t.co/pTREBd3wW7

RT @FDAfood: ⚠️FDA & @CDCgov are investigating a multi-state #outbreak of #Salmonella linked to #tahini produced by Achdut Ltd.… https://t.co/SqNgquDTAW

2/3: Older predicates used to determine substantial equivalence may not reflect the most modern device tech or #FDA’s latest understanding of a device’s benefits and risks. We’re looking to move the market toward reliance on newer predicates, w/ modern safety/performance features

3/3: Look for more from #FDA as we continue to advance this new policy framework. We believe that encouraging product developers to use more recent predicates will advance health technology and lead to more competition in the marketplace.

To successfully advance tools like Cas9 to improve health; we'll need more than just laws to ensure these tools aren't misused and abused. The scientific community must enforce without mercy strict standards on the moral and ethical limits of how these technologies should be used QT @angelicalavito: Amid uproar, Chinese scientist defends creating gene-edited babies - STAT https://t.co/3nHixuK7aY)

Certain uses of science should be judged intolerable, and cause scientists to be cast out. The use of CRISPR to edit human embryos or germ line cells should fall into that bucket. Anything less puts the science and the entire scientific enterprise at risk. https://t.co/OPE7r91ADY

RT @FDAMedia: FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma. The agency has now appro… https://t.co/vXK81fbDyh

THREAD: Today the #FDA approved a treatment for patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation https://t.co/6TAO0VKAyc 1/3

Today, we’re adding Estonia as part of our commitment to high-quality manufacturing, as we seek to ensure the quality of products sold in the U.S. regardless of where they’re manufactured. https://t.co/dBF4vj4L1P

RT @FDAOncology: #FDAOncology network lunch with cancer patient advocates at yesterday's #OCEPIP18 workshop. Save the date: Oct. 8,… https://t.co/oXFoA8ZmTO

This month, we recognized Belgium, Denmark, Finland and Latvia as capable under the Mutual Recognition Agreement (MRA). This means we’re able to avoid duplication of inspections and focus on sites that pose the greatest risk. https://t.co/dBF4vj4L1P

THREAD: To maximize our inspectional resources and efficiency, we’ve been collaborating with the European Union to allow drug inspectors to rely on information from inspections conducted within each other’s borders. https://t.co/dBF4vj4L1P https://t.co/ZAIaYAunAh

Today, #FDA updated its web page on the romaine linked E. coli outbreak to provide more specific information to consumers about the counties of concern in the Central Coast growing regions of northern and central CA https://t.co/IQTbLB9eoO https://t.co/Q7nlcpQdyu

3/3 Today’s approval targets this gene and is the first drug to be approved that can be used alone in patients who have this mutation who have relapsed or who don’t respond to initial treatment.

We’re taking new steps to bring some of the most significant modernizations to the FDA’s 510(k) program in a generation to help ensure new devices are evaluated against advances in technology that can improve safety and performance. https://t.co/EudSYtpWt0 https://t.co/aJgNOwZUwJ

RT @FDA_Drug_Info: Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions meeting begins this morning at 9am EST… https://t.co/qgKJFRITYM

RT @ZacharyBrennan: a quick look at today's #DrugShortagesMtg, where an FDA economist noted that shortages aren't just increasing but a… https://t.co/hW9ot8BUY7

1/3: Today I issued a statement that further explains why predicate modernization in the 510K medical device approval pathway is a key component of promoting innovation to help patients access safe and effective treatments. https://t.co/D6a74fT9Pa https://t.co/VlxpijPsa4

#FDA is committed to ensuring patients and healthcare providers have the most up-to-date information regarding ARB recalls. We’ll continue to post updates and recently posted a Q&A for patients and HCPs: https://t.co/EXl8c3HEIU

We've updated our list of valsartan products under recall to include certain lots of valsartan produced by Teva which contain the impurity NDEA. #FDA is carefully assessing all ARB medications and will continue to investigate. https://t.co/bRwqdjWIhR

RT @FDAOncology: Proposed patient-friendly definition of Progression-Free Survival: The amount of time after the start of this treat… https://t.co/pTREBd3wW7

RT @FDAfood: ⚠️FDA & @CDCgov are investigating a multi-state #outbreak of #Salmonella linked to #tahini produced by Achdut Ltd.… https://t.co/SqNgquDTAW

2/3: Older predicates used to determine substantial equivalence may not reflect the most modern device tech or #FDA’s latest understanding of a device’s benefits and risks. We’re looking to move the market toward reliance on newer predicates, w/ modern safety/performance features

3/3: Look for more from #FDA as we continue to advance this new policy framework. We believe that encouraging product developers to use more recent predicates will advance health technology and lead to more competition in the marketplace.

To successfully advance tools like Cas9 to improve health; we'll need more than just laws to ensure these tools aren't misused and abused. The scientific community must enforce without mercy strict standards on the moral and ethical limits of how these technologies should be used QT @angelicalavito: Amid uproar, Chinese scientist defends creating gene-edited babies - STAT https://t.co/3nHixuK7aY)

Certain uses of science should be judged intolerable, and cause scientists to be cast out. The use of CRISPR to edit human embryos or germ line cells should fall into that bucket. Anything less puts the science and the entire scientific enterprise at risk. https://t.co/OPE7r91ADY

RT @FDAMedia: FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma. The agency has now appro… https://t.co/vXK81fbDyh

THREAD: Today the #FDA approved a treatment for patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation https://t.co/6TAO0VKAyc 1/3

Today, we’re adding Estonia as part of our commitment to high-quality manufacturing, as we seek to ensure the quality of products sold in the U.S. regardless of where they’re manufactured. https://t.co/dBF4vj4L1P

RT @FDAOncology: #FDAOncology network lunch with cancer patient advocates at yesterday's #OCEPIP18 workshop. Save the date: Oct. 8,… https://t.co/oXFoA8ZmTO

This month, we recognized Belgium, Denmark, Finland and Latvia as capable under the Mutual Recognition Agreement (MRA). This means we’re able to avoid duplication of inspections and focus on sites that pose the greatest risk. https://t.co/dBF4vj4L1P

THREAD: To maximize our inspectional resources and efficiency, we’ve been collaborating with the European Union to allow drug inspectors to rely on information from inspections conducted within each other’s borders. https://t.co/dBF4vj4L1P https://t.co/ZAIaYAunAh

Today, #FDA updated its web page on the romaine linked E. coli outbreak to provide more specific information to consumers about the counties of concern in the Central Coast growing regions of northern and central CA https://t.co/IQTbLB9eoO https://t.co/Q7nlcpQdyu

3/3 Today’s approval targets this gene and is the first drug to be approved that can be used alone in patients who have this mutation who have relapsed or who don’t respond to initial treatment.